November 11, 2019 Clinical Research/Diagn. M&A, Partnerships

Abcam agrees to acquire Expedeon’s Proteomics and Immunology business, expanding offerings into the fast-growing conjugation segment

Acquisition of leading protein conjugation technologies and products with wellknown industry brands, including Lightning-Link® and CaptSureTM Complementary to Abcam’s existing antibody and multiplex growth strategy, with high customer overlap Acquisition expected to be accretive from the first full year of ownership (FY21)1 and to deliver a ROIC (pretax) ahead of the Group’s WACC by the... Read more

November 8, 2019 Clinical Research/Diagn. M&A, Partnerships

Abcam and BrickBio Announce a Partnership to Incorporate Conjugation-Ready Sites into Recombinant Antibodies Across Abcam’s Portfolio

BrickBio’s technology enables efficient placement of unnatural amino acids into recombinant antibodies at specific sites Together, the organizations will industrialize the technology to serve both the research and diagnostic markets CAMBRIDGE, UK and BOSTON, MA, USA, November 08, 2019 / B3C newswire / — Abcam plc, a global innovator in life science reagents and tools, is today pleased... Read more

November 6, 2019 Clinical Research/Diagn. Industrial

GE Healthcare opens lab for life science start-ups at Alderley Park, United Kingdom

NOVEMBER 06, 2019 By GE Healthcare Life Sciences • Lab will support acceleration of biotechnology, health and life sciences research in the UK• Companies to gain access to fully-equipped lab with the latest GE Healthcare Life Sciences technologies GE Healthcare Life Sciences will inaugurate an open-access lab at Alderley Park’s Mereside Campus, the UK’s largest single-site life sciences... Read more

November 5, 2019 Clinical Research/Diagn. PAI Top-10

QIAGEN expands portfolio of immuno-oncology assets for future companion diagnostics and biomarkers

Collaborates with Repertoire Genesis for access to T-cell /B-cell receptor repertoire assays for clinical next-generation sequencing Acquires licensing rights for epigenomic (DNA methylation) immune checkpoint inhibitor biomarkers developed by researchers from the University of Bonn Receives exclusive license to novel mRNA gene expression signatures from STRATIFYER Molecular Pathology GmbH which may guide treatment decisions for... Read more

October 29, 2019 Clinical Research/Diagn. Lab Top-10 Licensing, IP, and Legal

PerkinElmer Genomics’ Clinical Labs in U.S. and Malaysia to Process Samples with Vanadis Fully Automated NIPT Platform

Technology Provides Pregnant Women Widespread NIPT Access WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 29, 2019– PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that PerkinElmer Genomics will begin processing samples with the Vanadis® fully automated non-invasive prenatal testing (NIPT) system at its state-of-the-art CLIA and CAP-certified clinical laboratory in Pittsburgh,... Read more